Husby G
Am J Med. 1986 Nov 28;81(5B):6-10.
The largest multicenter, double-blind trial comparing piroxicam with naproxen in the treatment of osteoarthritis has recently been conducted in Norway. More than 2,000 patients were enrolled in the 12-week study. Both drugs showed similar efficacy, and serious gastrointestinal side effects occurred in less than 1 percent of the patients taking either agent. These findings are similar to results with other nonsteroidal anti-inflammatory drugs. This study indicates that in the treatment of osteoarthritis, piroxicam is as effective as naproxen and poses no greater risk of serious gastrointestinal side effects.
挪威最近进行了一项规模最大的多中心双盲试验，比较吡罗昔康与萘普生治疗骨关节炎的效果。超过2000名患者参与了这项为期12周的研究。两种药物疗效相似，服用任何一种药物的患者中出现严重胃肠道副作用的比例均不到1%。这些发现与其他非甾体抗炎药的结果相似。这项研究表明，在治疗骨关节炎方面，吡罗昔康与萘普生疗效相当，且不会带来更大的严重胃肠道副作用风险。
